QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:EOLS

Evolus Stock Forecast, Price & News

$5.40
-0.30 (-5.26%)
(As of 11/29/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.33
$5.91
50-Day Range
$5.40
$8.38
52-Week Range
$3.06
$17.38
Volume
525,148 shs
Average Volume
886,580 shs
Market Capitalization
$300.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.34
30 days | 90 days | 365 days | Advanced Chart
Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.


Evolus logo

About Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
119
Year Founded
N/A

Sales & Book Value

Annual Sales
$56.54 million
Book Value
$1.75 per share

Profitability

Net Income
$-163.01 million
Net Margins
-162.78%
Pretax Margin
-162.95%

Debt

Price-To-Earnings

Miscellaneous

Free Float
51,353,000
Market Cap
$300.12 million
Optionable
Optionable

Company Calendar

Last Earnings
3/23/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/23/2022

MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

518th out of 1,392 stocks

Pharmaceutical Preparations Industry

242nd out of 670 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Evolus (NASDAQ:EOLS) Frequently Asked Questions

Is Evolus a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Evolus stock.
View analyst ratings for Evolus
or view top-rated stocks.

How has Evolus' stock price been impacted by Coronavirus?

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has decreased by 8.6% and is now trading at $5.40.
View which stocks have been most impacted by COVID-19
.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Evolus
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The firm earned $20.58 million during the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative net margin of 162.78% and a negative trailing twelve-month return on equity of 145.33%.
View Evolus' earnings history
.

What price target have analysts set for EOLS?

8 analysts have issued twelve-month target prices for Evolus' shares. Their forecasts range from $7.00 to $25.00. On average, they anticipate Evolus' share price to reach $15.50 in the next twelve months. This suggests a possible upside of 187.0% from the stock's current price.
View analysts' price targets for Evolus
or view top-rated stocks among Wall Street analysts.

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • David Moatazedi, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Lauren P. Silvernail, Chief Financial Officer, EVP-Corporate Development
  • Rui Avelar, Chief Medical Officer, Head-Research & Development (LinkedIn Profile)
  • Dan Stewart, Vice President & General Manager
  • Kurt Knab, Vice President-Sales

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.91%), First Manhattan Co. (3.65%), Geode Capital Management LLC (1.03%), HealthInvest Partners AB (0.54%), Stonepine Capital Management LLC (0.54%) and Goldman Sachs Group Inc. (0.52%). Company insiders that own Evolus stock include Alphaeon 1 Llc, David Moatazedi, Lauren P Silvernail, Medytox Inc, Rui Avelar and Vikram Malik.
View institutional ownership trends for Evolus
.

Which institutional investors are selling Evolus stock?

EOLS stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Invesco Ltd., Two Sigma Investments LP, Squarepoint Ops LLC, California State Teachers Retirement System, Goldman Sachs Group Inc., Citadel Advisors LLC, and New York State Common Retirement Fund. Company insiders that have sold Evolus company stock in the last year include Alphaeon 1 Llc, David Moatazedi, Lauren P Silvernail, Rui Avelar, and Vikram Malik.
View insider buying and selling activity for Evolus
or view top insider-selling stocks.

Which institutional investors are buying Evolus stock?

EOLS stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., Stonepine Capital Management LLC, HealthInvest Partners AB, Millennium Management LLC, Castle Hook Partners LP, Trexquant Investment LP, Summit Global Investments, and Dynamic Technology Lab Private Ltd.
View insider buying and selling activity for Evolus
or or view top insider-buying stocks.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $5.40.

How much money does Evolus make?

Evolus has a market capitalization of $300.12 million and generates $56.54 million in revenue each year. The company earns $-163.01 million in net income (profit) each year or ($3.78) on an earnings per share basis.

How many employees does Evolus have?

Evolus employs 119 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

Where are Evolus' headquarters?

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at (949) 284-4555 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.